Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
12. April 2021 06:58 ET
|
Myovant Sciences, Inc.
SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 yearsContraceptive...
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
05. April 2021 06:58 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren...
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
29. März 2021 06:58 ET
|
Myovant Sciences, Inc.
If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in EuropeRelugolix is FDA-approved and currently available in the U.S. under the trade...
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
24. März 2021 06:30 ET
|
Myovant Sciences, Inc.
78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52...
Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
23. März 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of...
Myovant Sciences to Present at Upcoming Investor Conferences
22. Februar 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public...
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
17. Februar 2021 17:02 ET
|
Myovant Sciences, Inc.; Pfizer Inc.
LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline Achieved six of seven key secondary endpoints including...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
17. Februar 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
16. Februar 2021 08:32 ET
|
Myovant Sciences, Inc.
Six women reflect on their period experiences and journeys to self-advocacy in new video series Video stories and additional information about “Voices of Periods” now available on...
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
11. Februar 2021 06:55 ET
|
Myovant Sciences, Inc.
ORGOVYX™ (relugolix) approved by the U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer;...